Epistem Announces Tuberculosis Diagnostic Collaboration
EpiStem plc announced the formation of a tuberculosis (TB) diagnostic collaboration with Xcelris Laboratories, one of India's Genomics research and Diagnostic testing companies. Epistem and Xcelris will be evaluating Epistem's Genedrive(TM) molecular device as part of India's RNTCP (Revised National Tuberculosis Control Programme) which started in 1997 and since 2006 has covered the whole of India to ensure the rapid diagnosis and treatment of TB sufferers.
The TB evaluation programme with Xcelris will continue through 2011, following which it is anticipated that it will be rolled out into a select number of remote locations prior to a full evaluation of market positioning.
Organizations
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.